Table 3. Analysis of the morphological characteristics of invasive breast tumors, as a function of the pre-COVID and COVID period.
| 2019 (pre-COVID) | 2020 (COVID) | P -value* | |
|---|---|---|---|
| n (%) | n (%) | ||
| Molecular subtype † | |||
| Luminal A-like | 26 (29.2) | 6 (11.8) | 0.018 |
| Luminal B-like | 37 (41.6) | 24 (47.0) | 0.529 |
| Luminal HER | 10 (11.2) | 4 (7.8) | 0.520 |
| Triple-negative | 9 (10.1) | 11 (21.6) | 0.062 |
| Pure HER2 | 7 (7.9) | 6 (11.8) | 0.548 |
| Notthingham † | |||
| Grade I | 13 (14.9) | 9 (18.8) | 0.230 |
| Grade II | 53 (60.9) | 22 (45.8) | |
| Grade III | 21 (24.1) | 17 (35.4) | |
| Progesterone receptor | |||
| Positive | 56 (62.2) | 27 (52.9) | 0.282 |
| Negative | 34 (37.8) | 24 (47.1) | |
| Estrogen receptor † | |||
| Positive | 74 (82.2) | 33 (66.0) | 0.030 |
| Negative | 16 (17.8) | 17 (34.0) | |
| HER2 a | |||
| Positive | 17 (19.1) | 9 (17.7) | 0.753 |
| Negative | 66 (74.2) | 40 (78.3) | |
| Not conclusive | 6 (6.7) | 2 (3.9) | |
| KI67 a | |||
| Positive | 89 (77.4) | 51 (86.4) | 0.154 |
| Ignored | 26 (22.6) | 8 (13.6) | |
†
Missing information; * p -value –Chi-square or Fisher test.